BETA
Your AI-Trained Oncology Knowledge Connection!
mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.
Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.
Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC
Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.
FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin
D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.
Navigating Relapse and Sequencing Treatment After BTK Inhibitors in MCL
Peter Martin, MD, discusses the complexities of treating relapsed MCL after treatment with a BTK inhibitor.
Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC
The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.
Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Redefining Frontline Therapy for Mantle Cell Lymphoma
Peter Martin, MD, discusses the shifting paradigm for treating fit, transplant-eligible patients with MCL.
First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes
The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.
Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer
TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.
Weekly Carfilzomib Combination Shows MRD Negativity in Multiple Myeloma
The safety profile of carfilzomib, lenalidomide, and dexamethasone was tolerable in fit patients with newly diagnosed multiple myeloma.
Perceptions of Dermatologic AEs Could Impact Treatment Adherence
A survey found that patients believed dermatologic AEs were more prevalent with anti-cancer therapies than what has been reported.
Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection
Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer
The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.
Dordaviprone Presents Therapeutic Option for Diffuse Midline Glioma Type
Consolidative Thoracic Radiotherapy Displays Safety, Efficacy in ES-SCLC
No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.
Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma
Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.
Nivolumab Plus Chemo Improved OS and PFS in Front-Line ES-SCLC
The median PFS and OS were 5.5 months and 11.2 months with nivolumab plus carboplatin/cisplatin and etoposide in patients with small cell lung cancer.
Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC
Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.
Newly Approved Agent for Diffuse Midline Glioma Shows Tolerable AE Profile
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma
A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.
Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group
No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.
Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population
Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.
Nirogacestat Receives European Approval for Treatment of Desmoid Tumors
The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.
Novel Vaccine Shows Early Responses in Pancreatic Cancer and CRC
Phase 1 data may support continued research of amphiphile lymph node–targeted immunotherapy in solid tumors.
Dorvdaiprone Exhibits Durability in H3 K27M-Mutated Diffuse Midline Glioma
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
Beyond the Tumor: Addressing Body Image in Oncology
Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.
Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures
Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.
Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC
Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C–mutated colorectal cancer population.
